电离辐射对内皮细胞分泌TXA2和PGI2的影响

本实验通过血管内皮细胞的体外培养,用RIA 法直接测定细胞培养液中,6-keto-PGF_(1a)和 TXB_2的含量并以此反映培养细胞合成分泌 PGI_2和 TXA_2的量。同时观察15Gyγ射线辐照前后的差别,以探索辐射损伤出血的原因。实验结果表明,在辐射后32小时中 TXA_2上升,PGI_2下降。正常组 PGI_2分泌量为 TXA_2的6倍。在血液内皮界面保持以 PGI_2为优势的平衡状态。γ-射线照射能激活内皮细胞中的环氧化酶和血栓素合成酶破坏这一平衡,使TXA_2的量增加,促使血小板在内皮细胞表面粘附聚集并释放平滑肌增殖因子,导致血管内皮细胞损伤,从而造成出血。     

清栓酶治疗脑梗塞疗效与血浆血栓素A2及前列环素之间的关系

应用清栓酶治疗不同病期脑梗塞３８例,总有效率８６．７％,发病后治疗时间越早,疗效越好。治疗前病人均有不同程度的ＴＸＡ２升高,ＰＧＩ２下降,急性期更为明显,治疗后ＴＸＡ２下降,ＰＧＩ２上升,使失调的ＰＧＩ２－ＴＸＡ２平衡得以恢复     

急性缺氧对冠状动脉内皮细胞释放ET-1、NO、PGI2的影响

冠状动脉内皮细胞能分泌多种血管收缩和舒张物质。其中缩血管物质以内皮素的缩血管作用最强 ,且作用持久。内皮源性舒张因子主要为ＮＯ和花生四烯酸代谢产物ＰＧＩ2 。三种内皮源性血管活性因子均通过旁分泌方式作用于血管内皮下的平滑肌细胞 ,调节局部血管紧张度和血流量。在体研究表明缺氧可引起内皮素 1、ＮＯ、ＰＧＩ2 合成分泌改变。但在体研究时血浆及组织匀浆中ＥＴ 1、ＮＯ、ＰＧＩ2 的浓度改变难以反映其在血管内皮细胞形成和释放的状况。国外有关缺氧对离体冠状动脉内皮细胞合成和释放ＥＴ 1、ＮＯ、ＰＧＩ2 影响的研究也才刚起…     

滇产回心草及回心康抗缺血心肌脂质过氧化作用及对前列环素／血栓素的影响

采用结扎大鼠冠脉造成急性心肌缺血模型,动态观测Ⅱ导联心电图ST段的变化,以S-T段上移为指标反映缺血程度,观察了滇产回心草及回心康对急性心肌缺血损伤的保护作用,同时检测血清SOD、MDA、PGI2和TXA2.结果表明,回心草及回心康均能显著减少S-T段上移,均以2 g/kg组为显著;其1 g/kg及2 g/kg均使心肌梗塞范围缩小(p＜0.05,p＜0.01);均使心肌缺血大鼠血清SOD显著提高(p＜0.05及p＜0.01);MDA显著降低(p＜0.05,p＜0.01).回心草及回心康还能提高大鼠血清PGI2水平,降低TXA2含量,以回心草2 g/kg及回心康2 g/kg为显著(p＜0.05),呈剂量依赖性.实验结果提示,回心草及回心康均具有抗心肌缺血及抗脂质过氧化作用,其提高PGI2/TXA2可能与其抗心肌缺血作用机制有关.     

络泰对大鼠实验性急性心肌缺血的保护作用及抗脂过氧化作用

采用结扎大鼠冠脉造成急性心肌缺血模型,观察了络泰（三七总皂甙的新型剂）抗实验性心肌缺血作用。结果表明,络泰对大鼠实验性急性心肌缺血有一定程度的保护作用,本品50mg/kg显著减少心电图S－T段的上多（P＜0．01）;络泰5mg/kg、50mg/kg和100mg/kg均显著降低血清CPK（P＜0．05,P＜0．01）;在缩小心肌梗塞范围方面也有一定作用,但统计学上没有显著性。络泰三个剂量组能显著提高SOD活性（P＜0．01）,降低MDA水平（P＜0．05）;本品50mg/kg和100mg/kg还能显著增加心肌缺血时血中PGI2水平（P＜0．05）,提示络泰心肌缺血的保护作用与抗脂过氧化作用有关,其促进PGI2合成作用可能与其抗心肌缺血有关。     

蝮蛇抗栓酶对实验性动脉粥样硬化与PGI2／TXA2平衡影响的观察

通过用蝮蛇抗栓酶（Ｓｖａｔｅ）防治家兔动脉粥样硬化（ＡＳ）实验,发现Ｓｖａｔｅ能明显减轻家兔主动脉ＡＳ;同时能明显降低血液血栓素含量,能明显升高血液前列环素含量。以上血液检查结果与Ｓｖａｔｅ治疗心脑血管疾病时临床检查结果一致。说明Ｓｖａｔｅ有防治ＡＳ的作用,其机制与Ｓｖａｔｅ具有恢复前列环素／血栓素平衡的作用密切相关。     

高原肺水肿患者血浆ET-1、TXB2及6-Keto-PGF1a水平的变化

内皮素 (ＥＴ 1 )、血栓素Ａ2 (ＴｘＡ2 )、前列环素 (ＰＧＩ2 )与心、肺疾病发病的关系受到了广泛重视 ,但在高原肺水肿 (ＨＡＰＥ)发病中的作用国内报道尚少。为此本研究测定了 8例ＨＡＰＥ患者的血浆ＥＴ 1含量以及ＴｘＡ2 、ＰＧＩ2 代谢产物血栓素Ｂ2 (ＴｘＢ2 )6 酮 前列腺素Ｆ1ａ(6 ｋｅｔｏ ＰＧＦ1ａ)含量变化 ,探讨其在ＨＡＰＥ发病中的变化及意义。1　材料与方法(1 )受试对象　 8例ＨＡＰＥ患者均来自海拔 430 0ｍ以上边防哨卡和新藏公路沿线民工 ,汉族男性 ,年龄 2 0～ 45岁 ,平均30 6岁 ,平原出生 ,进驻高原 3～ 5ｄ发病…     

幼年大鼠诱发排卵条件下卵巢前列腺素(PGs)的含量变化及其生理作用

本实验用幼年大鼠经PMSG/hCG诱发排卵,研究了印巢PGE_2、PGF_(2α) 、6-酮-PGF_(1α) 及TXB_2在排卵过程中的变化。实验表明卵巢PGE_2、PGF_(2α) 及6-酮-PGF_(1α) 在排卵前达到峰值,在排卵后,均趋下降。TXB_2未出现明显变化。受试动物经消炎痛处理后,不仅使排卵受到严重抑制,而对上述三种PGs在排卵前的上升也表现了显著的抑制。提示在卵泡破裂过程中PGs的重要调节作用,PGE_2、PGF_(2α)均可能参与排卵,其中尤以PGE_2的作用最为显著。     

The PGI2-analogue iloprost and the TXA2-receptor antagonist sulotroban synergistically inhibit TXA2-dependent platelet activation

The stable PGI2-analogue iloprost and the TXA2-receptor antagonist sulotroban (BM 13177) were investigated for possible synergistic effects on platelet aggregation in human platelet rich plasma in vitro. Iloprost and sulotroban synergistically inhibited U 46619, collagen, and the second wave of ADP-induced platelet aggregation. Iloprost and sulotroban at concentrations showing little or no inhibition alone resulted, in combination, in marked or complete inhibition of U 46619 or collagen induced aggregation. Combination of iloprost 10(-10) M, which had no effect on the concentration-response curve (CRC) to U 46619, with sulotroban 5 x 10(-6) M, which shifted the CRC to U 46619 by a factor of 3 to the right, resulted in a rightward shift of the U 46619 CRC by a factor of 4.5. To attain a 4.5-fold shift with either compound alone, a concentration of 5 x 10(-10) M iloprost or 10(-5) M sulotroban was required. A similar mutual enhancement of inhibitory effects was seen for combinations of the PGI2-analogue cicaprost (ZK 96.480) with sulotroban or the TXA2-receptor antagonist SQ 29548 with iloprost. When the TXA2-dependent part of collagen-induced aggregation was fully inhibited by sulotroban, the concentrations of iloprost necessary for 90% inhibition were reduced by a factor of 2.5 - 3. In the presence of acetylsalicylic acid, the synergistic action of sulotroban and iloprost was reduced and merely additive effects against U 46619-induced platelet aggregation were found, suggesting that the release of endogenous TXA2 plays an important role for the synergistic effect of the two compounds. The combination of a PGI2-analogue and a TXA2-antagonist may lead to a safer and more effective control of platelet activation than with either compound alone.     

Synthesis of prostaglandins, TXA2 and PGI2, during one lung anesthesia

This study is to determine histamine, serotonin, TXA2 and PGI2 to be the cause of Hypoxic Pulmonary Vasoconstriction (HPV) at the same time of one lung ventilation and thoracotomy. Five patients who were to undergo upper-lobe resection of the right lung, were included in this study. All patients underwent same premedication and anesthetic method. Endotracheal intubation was done with a Univent tracheal tube. Gas analysis and determinations of the substances were done at six times in total. Respiratory Index (RI) began to increase immediately after the start of one lung ventilation. Post-thoracotomy RI further increased. After closing of the thorax, RI returned to the control values. Serotonin and histamine showed no change in any case throughout the experiment. TXB2 began to increase along with the start of one lung ventilation. The 15-min value was 167.2 +/- 85.8 pg/ml and 30-min value was 345.6 +/- 261.2 pg/ml, showing significant increase. The values of 6-keto PGF1 alpha were 22.6 +/- 2.9 pg/ml (15-min value), 89.6 +/- 52.3 pg/ml (30-min value), 290.8 +/- 120.1 pg/ml (post opening value) and 84.4 +/- 21.3 pg/ml (post-closing value). In our study, we concluded that neither serotonin nor histamine was the direct factor of HPV. TXA2 was the direct chemical mediator of HPV and PGI2 showed a negative feedback to the pulmonary vasoconstriction.     

Nrf2及其药理性活化剂在糖尿病心血管并发症中的作用

糖尿病(DM)导致的心脑血管并发症是危害人类健康的重大疾病。氧化应激被认为是DM相关心血管并发症发生、发展的重要机制,但通过补充外源性抗氧化剂并未能使心血管疾病患者远期获益。核因子E2相关因子2(Nrf2)可增加内源性抗氧化酶的活性从而提高机体的抗氧化应激能力,可能是治疗糖尿病心血管并发症的一个重要靶点,提示靶向Nrf2药物的开发可能获得防治糖尿病相关血管并发症的新一代药物。本文就Nrf2在糖尿病相关心血管并发症发生、发展中的作用及其药理性活化剂对糖尿病(DM)相关心血管病变的治疗作用进行综述。     

血栓素A2与糖尿病心血管并发症

心血管疾病是现今导致病人发病和死亡的首要因素,很多因素在血管性疾病发病发展中起着重要作用,血栓形成是参与脑中风及急性冠状动脉综合症的首要因素。血栓素A2（TXA2）是一种强血小板活化因子,在糖尿病患者体内的合成显著增加,并通过作用于血栓素受体诱导血小板聚集,血管收缩,血栓形成参与糖尿病心血管并发症的发生发展。因此,以TXA2为靶点开发抗血栓类药物对心血管疾病起着预防及治疗作用。本文对TXA2介导的糖尿病血管并发症的发病机制,及以此为靶点开发的抗血栓药物进行综述,为糖尿病心血管并发症的治疗及新型低副作用抗血栓药物的研发提供新的靶点。     

Comparative effects of some 3-amino 4,6-diarylpyridazines on the biosynthesis in vitro of TXA2 and PGI2- and on the TXA2- and PGI2-synthesizing activities of cardiac tissue

Some 3-amino 4,6-diarylpyridazine derivatives were tested for their effects on TXA2 and PGI2 biosyntheses in vitro and on the TXA2- and PGI2-synthesizing activities of cardiac tissue. Horse platelet and aorta microsomes were used as sources of thromboxane and prostacyclin synthetases respectively. The TXA2- and PGI2-synthesizing activities of cardiac tissue were studied on isolated perfused rabbit hearts (the heart microsomes being used both as TXA2 synthetase and PGI2 synthetase sources). TXB2 and 6-keto PGF1 alpha were determined by RIA. Among the compounds under study, 3-morpholino 4,6-diphenylpyridazine (III) was shown to inhibit specifically the TXA2 synthetase. Substitution of the morpholino group by a dimethylamino one (I) reinforced the inhibiting effects on TXA2 synthetase but it also revealed a slight anti-prostacyclin synthetase action of the molecule. Replacement of 3-morpholino moieties by either a 3-hydrazino (IV), or a 2-dimethylaminoethylamino (V), or a 2-morpholinoethylamino group (VI) abolished completely the effects of the molecule on TXA2 and PGI2 synthetases. Likewise the addition of chlorine on the para-position on the phenyl ring of I neutralized all its inhibitory effects both on TXA2 and PGI2 synthetases in vitro. None of the 3-amino 4,6-diarylpyridazine derivatives was active on either the TXA2- or PGI2-synthesizing activities of cardiac tissue.     

Rest/Activity Rhythms and Cardiovascular Disease in Older Men

Prior studies have suggested an increased risk of cardiovascular disease (CVD)-related mortality in older adults with disturbed circadian rest/activity rhythms (RARs). The objective goal of this study was to examine the association between disrupted RARs and risk of CVD events in older men. A total of 2968 men aged 67 yrs and older wore wrist actigraphs for 115?±?18 consecutive hours. RAR parameters were computed from wrist actigraphy data and expressed as quartiles (Q). CVD events consisted of a composite outcome of coronary heart disease (CHD), stroke, and peripheral vascular disease (PVD) events. Secondary analyses examined associations between RARs and individual components of the composite outcome (CHD, stroke, and PVD). There were 490 CVD events over an average of 4.0?±?1.2 yrs. Overall, reduced amplitude (HR?=?1.31, 95% confidence interval [CI] 1.01–1.71 for Q2 vs. Q4) and greater minimum (HR?=?1.33, 95% CI 1.01–1.73 for Q4 vs. Q1) were associated with an increased risk of CVD events in multivariable-adjusted models. In secondary analyses, there was an independent association between reduced amplitude (HR?=?1.36, 95% CI 1.00–1.86) and greater minimum activity counts (HR?=?1.39, 95% CI 1.02–1.91) with increased risk of CHD events. Reduced F value (HR?=?2.88, 95% CI 1.41–5.87 for Q1 vs. Q4 and HR?=?2.71, 95% CI 1.34–5.48 for Q2 vs. Q4) and later occurring acrophase of the RAR (HR?=?1.65, 95% CI 1.04–2.63 for Q4 vs. Q2–3) were associated with an increased risk of PVD events. Results were similar in men without a history of CVD events. The findings revealed that among older men, measures of decreased circadian activity rhythm robustness (reduced amplitude and greater minimum activity) were associated with an increased risk of CVD events, primarily through increased risk of CHD or stroke events, whereas measures of reduced circadian activity rhythmicity were not associated with risk of CVD events overall, but were associated with an increased risk of PVD events. These results should be confirmed in other populations. (Author correspondence: E-mail: ames0047@umn.edu)     

Papaverine effects on PGI2 and TXA2 release from the canine vascular wall.

Operative manipulation of blood vessels might lead to spasm, thereby destroying the endothelial cell function: the spasm can be prevented by the vasodilator papaverine. To study if this was mediated via the prostanoid pathway the following investigation was undertaken: canine jugular veins and carotid arteries were dissected with or without papaverine. Vessel segments were then perfused with Hank's balanced salt solution for five times 15 min. Prostacyclin was measured as the stable degradation product 6-keto-PGF1 alpha and thromboxane as TXB2, by radioimmunoassay. Control arterial segments' 6-keto-PGF1 alpha release was initially 129.5 + 20.1 pg/mm2/15 min, and 29.7 + 10.4 after 60 min (p less than 0.05 vs initial value) and responded to arachidonic acid (AA) with an increase to 139.2 +/- 23.1 pg/mm2/15 min (p less than 0.05). Segments treated with papaverine had the same release as the controls. In venous segments there was a lower initial release (p less than 0.05) from segments given papaverine than from controls, but this was more likely an effect of papaverine on the assay. There was no difference in release of prostacyclin from segments given papaverine in the perfusate compared to controls when using 125I tracer. When using 3H tracer including absorption of free antigen to dextran coated charcoal, papaverine displaced the free tracer giving artificially low values. There was no effect of papaverine given intraoperatively on the TXB2 release, neither from arteries nor from veins. In another experiment the vessel wall tension was examined and the cyclooxygenase inhibitor diclofenac did not inhibit the vasodilating effect of papaverine.(ABSTRACT TRUNCATED AT 250 WORDS)     

达格列净抑制2型糖尿病小鼠心血管及肾脏并发症的研究

摘要 目的：探讨达格列净对2型糖尿病小鼠心、肾的保护作用。方法：选取24只6周龄的雄性2型糖尿病模型(C57BLKS/J-leprdb/leprdb, db/db)小鼠,随机等分成达格列净投药组和对照组,另选取同周龄雄性非糖尿病的(C57BLKS/J-leprdb/+, db/m)小鼠12只作为正常组。检测小鼠血糖后,从第7周开始对投药组小鼠进行为期10周的达格列净用药,其余小鼠给予同等计量生理盐水,期间定期监测血糖、血压、尿糖以及各项代谢相关指标。投药结束后分离心脏及肾脏组织,组织切片进行染色观察。结果：与对照组相比,投药组达格列净用药后第1周血糖值显著降低(P < 0.01),用药9周后糖耐量测试结果显示血糖值几乎接近正常小鼠组水平,但各组间血压值无明显差异,心肌间质纤维化、炎性细胞浸润、氧化应激水平明显下降,同时肾小球硬化、炎性细胞浸润和氧化应激程度明显得到改善。结论：达格列净用药不仅能显著降低2型糖尿病模型小鼠血糖,还能有效抑制糖尿病引起的心血管及肾损害。